Found: 5
Select item for more details and to access through your institution.
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection.
- Published in:
- Parasitology Research, 2021, v. 120, n. 12, p. 4037, doi. 10.1007/s00436-021-07342-1
- By:
- Publication type:
- Article
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
- Published in:
- Parasitology Research, 2021, v. 120, n. 1, p. 321, doi. 10.1007/s00436-020-06971-2
- By:
- Publication type:
- Article
A urine-based ELISA with recombinant non-glycosylated SARS-CoV-2 spike protein for detecting anti-SARS-CoV-2 spike antibodies.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-31382-5
- By:
- Publication type:
- Article
Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
- Published in:
- Parasite Immunology, 2020, v. 42, n. 12, p. 1, doi. 10.1111/pim.12784
- By:
- Publication type:
- Article
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
- Published in:
- Medical Microbiology & Immunology, 2021, v. 210, n. 2/3, p. 133, doi. 10.1007/s00430-021-00707-4
- By:
- Publication type:
- Article